Key Takeaways
•BioDuro has inaugurated a state-of-the-art solid-phase peptide synthesis scale-up facility in Shanghai, enhancing its capacity to meet the growing global demand for efficient and scalable peptide manufacturing.
•The facility is equipped with advanced automated synthesizers and supports the production of various peptide molecules, including linear and cyclic peptides, as well as peptide drug conjugates.
•This expansion enables seamless integration of peptide projects from discovery to development, offering clients flexibility and customization in peptide synthesis.
BioDuro, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the opening of a fully automated solid-phase peptide synthesis scale-up laboratory at its Shanghai Zhangjiang High-tech Park campus in China. This strategic expansion is designed to bolster the company’s peptide synthesis capabilities, addressing the increasing demand from global partners for efficient and scalable peptide manufacturing.
The state-of-the-art facility is equipped with automated solid-phase peptide synthesizers, cleavage systems, and freeze-drying equipment, supporting peptide synthesis scale-up to 800 mmol. This infrastructure enables the production of a wide range of peptide molecules, including linear peptides, cyclic peptides, and various peptide drug conjugates (PDC).
Integration of Peptide Projects from Discovery to Development
Complementing BioDuro’s peptide discovery synthesis center at its Beijing campus, which focuses on early-stage research and development, the new Shanghai laboratory facilitates seamless integration of peptide projects from discovery through to development. The chemistry teams at both campuses specialize in solid-phase and liquid-phase peptide synthesis, providing additional flexibility and customization for clients.
This integrated approach ensures that peptide projects can transition smoothly from initial discovery phases to large-scale manufacturing, maintaining consistency and quality throughout the process.
Meeting the Rising Demand for Peptide-Based Programs
The opening of this new laboratory comes in response to a considerable increase in demand for peptide-based programs. Dr. Armin Spura, CEO of BioDuro, commented, “Demand for peptide-based programs has increased considerably, and the opening of this new laboratory provides BioDuro’s customers with a significant step forward in addressing the capabilities required to scale their candidates to compete in this fast-growing field.”
This development underscores BioDuro’s commitment to continuously advancing its CRDMO capabilities and capacity, driving breakthroughs that deliver life-changing therapies to patients worldwide.
Comprehensive Peptide Platform and Integrated Services
BioDuro’s comprehensive peptide platform integrates biology and Drug Metabolism and Pharmacokinetics (DMPK) services, offering a one-stop-shop solution to accelerate peptide development. This integrated approach is intended to ensure streamlined processes and efficient collaboration, helping clients bring innovative peptide therapeutics to market faster.
By providing end-to-end services, BioDuro enables clients to focus on the core aspects of drug discovery and development, while leveraging the company’s expertise in peptide chemistry and manufacturing.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
